125 related articles for article (PubMed ID: 25587837)
1. Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.
Ribeiro RP; Gasparetto JC; de Oliveira Vilhena R; Guimarães de Francisco TM; Martins CA; Cardoso MA; Pontarolo R; de Carvalho KA
Bioanalysis; 2015; 7(2):207-20. PubMed ID: 25587837
[TBL] [Abstract][Full Text] [Related]
2. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Bugamelli F; Marcheselli C; Barba E; Raggi MA
J Pharm Biomed Anal; 2011 Feb; 54(3):562-7. PubMed ID: 21035976
[TBL] [Abstract][Full Text] [Related]
3. A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.
Vilhena Rde O; Pontes FL; Marson BM; Ribeiro RP; de Carvalho KA; Cardoso MA; Pontarolo R
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 967():41-9. PubMed ID: 25063927
[TBL] [Abstract][Full Text] [Related]
4. Micellar HPLC-UV method for the simultaneous determination of levodopa, carbidopa and entacapone in pharmaceuticals and human plasma.
Belal F; Ibrahim F; Sheribah ZA; Alaa H
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():36-45. PubMed ID: 29843067
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a high-performance liquid chromatography-electrospray ionization-MS/MS method for the simultaneous quantitation of levodopa and carbidopa in human plasma.
César IC; Byrro RM; Santana E Silva Cardoso FF; Mundim IM; Souza Teixeira L; Gomes SA; Bonfim RR; Pianetti GA
J Mass Spectrom; 2011 Sep; 46(9):943-8. PubMed ID: 21915959
[TBL] [Abstract][Full Text] [Related]
6. A rapid liquid chromatography/tandem mass spectrometry method for simultaneous determination of levodopa, carbidopa, entacapone and their six related compounds in film-coated tablets.
Burmaoğlu RE; Sağlık Aslan S
Rapid Commun Mass Spectrom; 2020 Jun; 34(12):e8782. PubMed ID: 32170976
[TBL] [Abstract][Full Text] [Related]
7. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Muhlack S; Herrmann L; Salmen S; Müller T
J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation.
César Ida C; Byrro RM; Cardoso FF; Mundim IM; Teixeira Lde S; da Silva EP; Gomes SA; Bonfim RR; Pianetti GA
J Pharm Biomed Anal; 2011 Dec; 56(5):1094-100. PubMed ID: 21856105
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous estimation of levodopa, carbidopa and 3-oxymethyldopa in rat plasma using HPLC-ECD.
Raut PP; Charde SY; Bishnoi P
Biomed Chromatogr; 2016 Oct; 30(10):1696-700. PubMed ID: 26910491
[TBL] [Abstract][Full Text] [Related]
10. Sensitive LC-MS/MS method for quantitation of levodopa and carbidopa in plasma: application to a pharmacokinetic study.
Ferreira MS; Davanço MG; Pepi GT; Previde N; Gabbai JJ; Martho AC; Brandão AH; Riccio MF; de Campos DR; Meulman J; Noboli AC; Júnior PS
Bioanalysis; 2018 Oct; 10(19):1567-1576. PubMed ID: 30295551
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a simple and sensitive method for quantification of levodopa and carbidopa in rat and monkey plasma using derivatization and UPLC-MS/MS.
Junnotula V; Licea-Perez H
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():47-53. PubMed ID: 23548675
[TBL] [Abstract][Full Text] [Related]
12. Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid.
Karimi M; Carl JL; Loftin S; Perlmutter JS
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May; 836(1-2):120-3. PubMed ID: 16584928
[TBL] [Abstract][Full Text] [Related]
13. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
Nyholm D; Ehrnebo M; Lewander T; Trolin CG; Bäckström T; Panagiotidis G; Spira J; Nyström C; Aquilonius SM
Acta Neurol Scand; 2013 Feb; 127(2):124-32. PubMed ID: 22762460
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous high-performance liquid chromatographic analysis of carbidopa, levodopa and 3-O-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection.
Titus DC; August TF; Yeh KC; Eisenhandler R; Bayne WF; Musson DG
J Chromatogr; 1990 Dec; 534():87-100. PubMed ID: 2094725
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of levodopa and carbidopa in rat plasma by LC-MS/MS: The key role of ion-pairing reversed-phase chromatography.
Chi J; Ling Y; Jenkins R; Li F
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jun; 1054():1-9. PubMed ID: 28412665
[TBL] [Abstract][Full Text] [Related]
16. Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS.
Yadav M; Dixit P; Trivedi V; Gandhi A; Senger A; Guttikar S; Singhal P; Shrivastav PS
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(5-6):533-40. PubMed ID: 19167276
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous estimation of levodopa and carbidopa by RP-HPLC using a fluorescence detector: its application to a pharmaceutical dosage form.
Raut PP; Charde SY
Luminescence; 2014 Nov; 29(7):762-71. PubMed ID: 24399763
[TBL] [Abstract][Full Text] [Related]
18. Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.
Müller T; Muhlack S
J Neural Transm (Vienna); 2014 Jun; 121(6):643-8. PubMed ID: 24390153
[TBL] [Abstract][Full Text] [Related]
19. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
20. Issues important for rational COMT inhibition.
Dingemanse J
Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
